Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» ARIAD Presents Analysis of Cardiovascular Risk Profile of Patients from Pivotal PACE Trial of Iclusig (Ponatinib)
ARIAD Presents Analysis of Cardiovascular Risk Profile of Patients from Pivotal PACE Trial of Iclusig (Ponatinib)
ARIAD Presents Analysis of Cardiovascular Risk Profile of Patients from Pivotal PACE Trial of Iclusig (Ponatinib)
Submitted by
admin
on June 1, 2013 - 12:16pm
Source:
Yahoo/BusinessWire
News Tags:
Iclusig
Ariad Pharmaceuticals
leukemia
Headline:
ARIAD Presents Analysis of Cardiovascular Risk Profile of Patients from Pivotal PACE Trial of Iclusig (Ponatinib)
Do Not Allow Advertisers to Use My Personal information
